• <rp id="mz6wu"><meter id="mz6wu"></meter></rp><rp id="mz6wu"></rp>
  • <ruby id="mz6wu"><optgroup id="mz6wu"></optgroup></ruby><rt id="mz6wu"><meter id="mz6wu"></meter></rt>

    <cite id="mz6wu"><form id="mz6wu"></form></cite><video id="mz6wu"><menuitem id="mz6wu"><option id="mz6wu"></option></menuitem></video>
    <source id="mz6wu"><nav id="mz6wu"></nav></source>
  • <tt id="mz6wu"></tt>
    <tt id="mz6wu"><noscript id="mz6wu"><samp id="mz6wu"></samp></noscript></tt><tt id="mz6wu"><noscript id="mz6wu"><label id="mz6wu"></label></noscript></tt>
  • Image by Solera
    March 5, 2018 | By Solera

    Review Finds Switching From Reference Product To Biosimilar ‘Not Inherently Dangerous’

    A review in the journal Drugs found that moving to a biosimilar from a reference drug “is not inherently dangerous, and that patients, healthcare professionals, and the public should not assume that it is problematic.” Researchers looked at data from 90 studies, finding no differences in safety or efficacy after numerous switches between the biologic and the biosimilar.

    Click Here to view the original article at Regulatory Affairs Professional Society

    A smaller focus to make a much larger impact. Our goal is to deliver on every promise we make

    Our Mission

    Learn More
    182tv